A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
- Xuping Xie
- Antonio E. Muruato
- Xianwen Zhang
- Kumari G. Lokugamage
- Camila R. Fontes-Garfias
- Jing Zou
- Jianying Liu
- Ping Ren
- Mini Balakrishnan
- Tomas Cihlar
- Chien-Te K. Tseng
- Shinji Makino
- Vineet D. Menachery
- John P. Bilello
- Pei-Yong Shi
Publication date
October 2020
DOI Publisher
Springer Science and Business Media LLC Journal
Nature CommunicationsAbstract
A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. To address this, Shi and colleagues present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV2-Nluc), and show that it has potential for large-scale vaccine evaluation and neutralizing antibody testing
Add to ORKG